Abeona Therapeutics Inc
ABEO
Company Profile
Business description
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Contact
6555 Carnegie Avenue
4th Floor
ClevelandOH44103
USAT: +1 646 813-4701
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
136
Stocks News & Analysis
stocks
Shares leap for ASX rare earths provider
We increased our fair value based on higher expected rare earths pricing.
stocks
Does SpaceX’s sky-high valuation make sense?
SpaceX’s $1.5 trillion valuation looks expensive and risky, but not irrational.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,838.00 | 42.40 | -0.48% |
| CAC 40 | 8,041.81 | 15.55 | -0.19% |
| DAX 40 | 23,640.03 | 328.60 | -1.37% |
| Dow JONES (US) | 47,417.27 | 289.24 | -0.61% |
| FTSE 100 | 10,353.77 | 58.47 | -0.56% |
| HKSE | 25,571.84 | 326.92 | -1.26% |
| NASDAQ | 22,716.13 | 19.03 | 0.08% |
| Nikkei 225 | 53,942.19 | 1,083.18 | -1.97% |
| NZX 50 Index | 13,199.29 | 104.92 | 0.80% |
| S&P 500 | 6,775.80 | 5.68 | -0.08% |
| S&P/ASX 200 | 8,614.80 | 28.40 | -0.33% |
| SSE Composite Index | 4,106.96 | 26.48 | -0.64% |